Immunological aspects of fresh-frozen allogeneic bone grafting for lateral ridge augmentation

Author(s)

Spin-Neto, Rubens ^{[1, 2]} ; Stavropoulos, Andreas ^{[3, 4]} ; de Freitas, Rubens Moreno ^{[1, 2]} ; Violin Dias Pereira, Luis Antonio ^[5] ; Carlos, Iracilda Zeppone ^[6] ; Marcantonio, Jr., Elcio ^{[1, 2]}

Affiliation

^[1] UNESP Univ Estadual Paulista, Araraquara Dent Sch, Dept Periodontol, Sao Paulo - Brazil

^[2] Aarhus Univ, Dept Dent Oral Radiol, DK-8000 Aarhus - Denmark

^[3] Aarhus Univ, Dept Dent Periodontol, Sch Dent, DK-8000 Aarhus - Denmark

^[4] Ctr Expt & Preclin Biomed Res, Athens - Greece

^[5] UNICAMP State Univ Campinas, Dept Histol & Embryol, Inst Biol, Sao Paulo - Brazil

^[6] UNESP Univ Estadual Paulista, Araraquara Pharmaceut Sci Sch, Dept Clin Anal, Sao Paulo - Brazil

• Document type: Journal article
• Source: Clinical Oral Implants Research; v. 24, n. 9, p. 963-968, SEP 2013.
• Web of Science Citations: 9

Abstract

Objectives: To present some immunological aspects of fresh-frozen allogeneic bone grafting for lateral bone augmentation, based on the quantitative evaluation of IL-10, IL-1 beta, IFN-gamma and TNF-alpha in patients sera. Material and methods: Thirty-three partially or totally edentulous patients received fresh-frozen allogeneic bone (AL - 20 patients) or autologous bone onlay block grafts (AT - 13 patients) prior to oral implant placement. Blood samples were collected from each patient at various time-points during a 6 month-period (baseline, 14, 30, 90 and 180 days postoperatively). Quantitative evaluation of IL-10, IL-1 beta, IFN-gamma and TNF-alpha was performed by enzyme linked immunosorbent assay (ELISA). Results: For all evaluated markers and at all evaluated periods, inter-group comparisons showed no statistically significant differences between the groups, while the observed values were within normal levels. For AL-treated patients, intra-group evaluation showed statistically significant increase of TNF-a from baseline to 90 (P < 0.001) and 180 (P < 0.01) days, and from 14 to 90 (P < 0.01) and 180 (P < 0.05) days. IFN-gamma showed intercalated results, with a decrease from baseline to 14 days (P < 0.05), and increase from 14 to 90 days (P < 0.001) and 180 (P < 0.05) days. No differences between the periods of evaluation were found for the AT group. Conclusions: AL grafting for lateral bone augmentation, similar to AT grafting, does not seem to challenge the immune system significantly. (AU)

• FAPESP's process: 08/09207-9 - Bone allografts in humans: immunologic, tomographic, histological and histometrical evaluation of their incorporation and capacity of implants osseointegration
• Grantee: Elcio Marcantonio Junior
• Support Opportunities: Regular Research Grants